SC
KITE

Sculptor Capital’s Kite Pharma, Inc. KITE Stock Holding History

Sculptor Capital’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-51,900
Closed -$4.07M – 438
2017
Q1 		$4.07M Hold
51,900
– – 0.02% 185
2016
Q4 		$2.33M Buy
+51,900
New +$2.55M 0.02% 230

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sculptor Capital's KITE Position: Q2 2017 in Review

Sculptor Capital sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 51,900 shares — an estimated $4.07M sold.

Sculptor Capital first reported a position in KITE in Q4 2016 and held it in 2 quarters. The position peaked at $4.07M in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

  • Sculptor Capital reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Sculptor Capital sold 51,900 Kite Pharma, Inc. shares in Q2 2017, an estimated $4.07M.
  • Sculptor Capital first reported a position in Kite Pharma, Inc. in Q4 2016 and held it in 2 quarters.
  • Sculptor Capital's Kite Pharma, Inc. position peaked at $4.07M in Q1 2017.
  • 220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Sculptor Capital's 13F filing for Q2 2017, filed 8 Aug 2017.